Clinical Pathology Department, Faculty of Medicine, Zagazig University, Sharqyiah Governorate, Zagazig 44519, Egypt.
Med Oncol. 2012 Jun;29(2):1119-26. doi: 10.1007/s12032-011-9895-y. Epub 2011 Mar 12.
We aimed to explore the expression of CD34 and its impact on the disease outcome in patients with APL. The study comprised 40 de novo APL patients. Diagnostic tools included peripheral blood and bone marrow morphology and cytochemistry, immunophenotyping, cytogenetic studies, and PML/RARα fusion gene detection using RT-PCR. CD34 was expressed in 13 (32.5%) of cases with higher expression in M3v compared to M3 subtype. All M3v cases were CD34+, while only 7.4% of M3 cases were CD34+. CD34+ cases were associated with significant higher white blood cell count and peripheral blood promyelocytes. No significant association was found between PML/RAR-α isoform and molecular remission. CD34+ expression was significantly associated with decreased incidence of molecular remission and increased incidence of early death. The overall survival of patients with WBC count >11 × 103/μl was inferior to patients with WBC count <11 × 103/μl, but no significant differences were observed in overall survival between CD34- and CD34+ or between bcr1 and bcr3 groups. Immunophenotypic analysis for CD34 could distinguish an APL subset with different biological characteristics and adverse prognostic outcome.
我们旨在探讨 CD34 的表达及其对 APL 患者疾病结局的影响。该研究纳入了 40 例初诊 APL 患者。诊断工具包括外周血和骨髓形态学及细胞化学、免疫表型、细胞遗传学研究,以及使用 RT-PCR 检测 PML/RARα 融合基因。在 13 例(32.5%)病例中表达了 CD34,其中 M3v 亚型的表达高于 M3 亚型。所有 M3v 病例均为 CD34+,而仅有 7.4%的 M3 病例为 CD34+。CD34+病例与显著更高的白细胞计数和外周血早幼粒细胞相关。未发现 PML/RAR-α 异构体与分子缓解之间存在显著相关性。CD34+表达与分子缓解发生率降低和早期死亡发生率增加显著相关。白细胞计数>11×103/μl 的患者总生存率低于白细胞计数<11×103/μl 的患者,但在 CD34-和 CD34+或 bcr1 和 bcr3 组之间,总生存率无显著差异。CD34 的免疫表型分析可以区分具有不同生物学特征和不良预后的 APL 亚群。